相关实验视频

Updated: Jun 17, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

在PD-L1结合化合物的体探索:基于结构的虚拟选,分子对接和MD模拟

Abdullah Alanzi¹, Ashaimaa Y Moussa², Ramzi A Mothana¹

¹Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

|August 9, 2024

概括

研究人员确定了潜在的新药物化合物,针对编程死亡连接体1 (PD-L1),以增强癌症免疫疗法. 这些化合物在早期体外研究中显示出抑制PD-L1活性的前景.

科学领域:

免疫学免疫学免疫学
计算化学的计算化学
药理学药理学是指药理学的学科.

背景情况:

编程死亡连接体1 (PD-L1) 是一种对免疫系统调节至关重要的跨膜蛋白.
癌症中PD-L1的过度表达使瘤细胞能够逃避免疫检测.
抑制PD-L1是癌症免疫学中一个有前途的治疗策略.

研究的目的:

通过基于结构的虚拟查来识别PD-L1抑制的新型小分子.
评估潜在候选药物的结合亲和力和稳定性.
通过ADMET分析评估已识别的化合物的药物相似性.

主要方法:

基于结构的药物库对PD-L1.1.进行虚拟选.
分子对接以确定最佳的结合姿势和亲和力.
吸收,分布,新陈代谢,分泌和毒性 (ADMET) 分析.
对顶级化合物的200 ns分子动力学模拟.

主要成果:

十种化合物对PD-L1具有很高的结合亲和度,从-10.734到-10.398 kcal/mol不等.
选择的化合物显示出有利的ADMET特性.
分子动力学模拟证实了结合稳定性,没有对PD-L1.1的显著构造变化.

结论:

已识别的化合物是PD-L1抑制的潜在主要候选物.
这些发现支持进一步进行体外研究,以开发新的癌症免疫疗法.
这项研究强调了计算方法在PD-L1向疗法的药物发现中的实用性.

更多相关视频

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

相关概念视频

Ligand Binding Sites

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...